OUR FOCUS
NK cell derived allogeneic therapies
Natural killer (NK) cells are an ideal foundation for off the shelf (allogeneic) cell therapy development. They are hard-coded to patrol the body looking for abnormal cells, and naturally perform a number of functions:
01
Natural Detection and Direct Killing of Cancer Cells
NK cells are named 'natural killer' cells based upon their innate ability to recognise and and directly kill cancer without any priming or prior activation. As part of our immune system, they also trigger indirect mechanisms for killing cancer cells.
02
Indirect Killing of Cancer Cells
Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill cancer cells.
02
A universal platform for off the shelf development.
The fact that NK cells have fail-safe mechanisms that prevent the killing of healthy cells makes them an ideal universal platform for allogeneic (off the shelf) development.
NATURAL KILLER (NK) CELL
CHM 0201
Core NK platform
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products.
-
Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows
-
CORE-NK platform cells are made by activating and expanding natural killer cells to make them more active and robust
-
CORE-NK platform cells have been studied in a phase 1 clinical trial in blood cancers and solid tumours
CHM 0301
Next gen. core NK platform
The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells.
Development of the next generation CORE-NK platform will be as a combination therapy for blood cancers
CHM 1301, CHM 2301 AMD CHM 3301
Building upon our core NK platform
Want to know more?
CLTX CAR NK
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen Receptor.
CDH17 CAR NK
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen Receptor.
UNDISCLOSED CAR NK
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen Receptor.